Principal Investigator
Philip Scheltens, MD
Alheimer Research Center, VU medisch centrum
- 4 trials
- 1 compound
Therapeutic focus
- Alzheimer Disease
- Mild Cognitive Impairment
- Tauopathies
- Alzheimer's Disease
All trials (4)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT04445831 | Phase 1/2 | Completed | JNJ-2056 (ACI-35.030) | Johnson & Johnson |
| NCT02423122 | Phase 2 | Completed | — | EIP Pharma Inc |
| NCT00285025 | Phase 2 | Completed | — | Sanofi |
| NCT00285077 | Phase 2 | Completed | — | Sanofi |
Compounds studied
Trial sites (15)
- Kuopio, Finland
- 's-Hertogenbosch, Netherlands
- Paris, France
- Helsinki, Finland
- Mölndal, Sweden
- Stockholm, Sweden
- Laval, Canada
- Berlin, Germany
- Midrand, South Africa
- Horslholm, Denmark
- Amsterdam, Netherlands
- Bromma, Sweden
- Edinburgh, United Kingdom
- Turku, Finland
- London, United Kingdom
Investigator and site data mirrored fromClinicalTrials.gov (public domain).